Shield Therapeutics Debt 2024

Shield Therapeutics Aktienanalyse

What does Shield Therapeutics do?

The company Shield Therapeutics PLC is a renowned British pharmaceutical conglomerate, founded in 2008. Based in Gateshead, England, Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. The company also has a strong presence in Europe and Asia. Shield Therapeutics' business model is to provide high-quality and innovative medical solutions to improve people's health and well-being. The company continuously researches new products to better cater to the needs of patients and doctors. The focus of Shield Therapeutics is on combating iron deficiency anemia, a severe blood disorder caused by a lack of iron in the body. Iron deficiency can be attributed to various factors, such as inadequate food intake, blood loss, or iron deficiency accumulation due to diseases. This anemia can lead to a range of symptoms, including fatigue, weak muscles, and dizziness. Long-term consequences can include life-threatening complications such as heart failure and strokes. Shield Therapeutics offers various products that can be used to treat iron deficiency anemia, such as Feraccru (in injection form) and Accrufer / Accrufer Tablets (in tablet form). Feraccru is an orally absorbed iron preparation indicated for the treatment of anemia in adults with iron deficiency anemia. Accrufer / Accrufer Tablets is an iron salt complex that is rapidly absorbed and shows high efficacy. The company also has its own research and development department, which focuses on researching innovative therapies and treatment methods. Shield Therapeutics actively participates in clinical research and the development of new therapeutic options aimed at improving the quality of life for people with iron deficiency anemia. More recently, Shield Therapeutics has also ventured into other disease areas. The company has developed clinical studies in collaboration with a top 10 pharmaceutical company to modify atherosclerosis through iron chelators. This is a groundbreaking research field that aims to develop advanced therapies for the treatment of infertility and chronic obstructive pulmonary disease (COPD). Overall, Shield Therapeutics has experienced strong growth in recent years and has solidified its position as a leading provider of pharmaceutical products for the treatment of iron deficiency anemia. The company has developed a wide range of products and can rely on a strong research and development department that constantly faces new challenges and offers innovative solutions for a variety of health issues. If Shield Therapeutics continues to be successful, it will undoubtedly continue to play a significant role in the industry. Answer: The company Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. Shield Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Shield Therapeutics's Debt Structure

Shield Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Shield Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Shield Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Shield Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Shield Therapeutics stock

What is the debt of Shield Therapeutics this year?

Shield Therapeutics has a debt level of 6.3 GBP this year.

What was the debt of Shield Therapeutics compared to the previous year?

The debt of Shield Therapeutics has increased by 268.03% compared to the previous year increased.

What are the consequences of high debt for investors in Shield Therapeutics?

High debt can pose a risk for investors of Shield Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Shield Therapeutics?

Low debt means that Shield Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Shield Therapeutics affect the company?

An increase in debt of Shield Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Shield Therapeutics affect the company?

A reduction in debt of Shield Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Shield Therapeutics?

Some factors that can influence the debt of Shield Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Shield Therapeutics so important for investors?

The debts of Shield Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Shield Therapeutics take to change the debt?

To change the debt, Shield Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Shield Therapeutics pay?

Over the past 12 months, Shield Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shield Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of Shield Therapeutics?

The current dividend yield of Shield Therapeutics is .

When does Shield Therapeutics pay dividends?

Shield Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shield Therapeutics?

Shield Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Shield Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shield Therapeutics located?

Shield Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shield Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shield Therapeutics from 9/9/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Shield Therapeutics pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Shield Therapeutics in the year 2023?

In the year 2023, Shield Therapeutics distributed 0 GBP as dividends.

In which currency does Shield Therapeutics pay out the dividend?

The dividends of Shield Therapeutics are distributed in GBP.